Data completeness
4/8 — Partial
Drug data last refreshed 11h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KLOXXADO is a naloxone hydrochloride nasal spray approved by the FDA for emergency treatment of opioid overdose. It rapidly reverses opioid effects by acting as a competitive antagonist at opioid receptors. This formulation addresses the critical need for accessible, easy-to-administer emergency overdose reversal in community and clinical settings.
$0.312MPart D
Peak7.9 years to LOEPeak lifecycle status indicates stable market presence with established commercial infrastructure; team size likely optimized but focused on market penetration and retention.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on KLOXXADO offers career stability in a peak-lifecycle specialty product with established market presence and clear commercial playbook. Roles emphasize execution excellence, market penetration, and competitive positioning rather than launch complexity or clinical innovation.
Brand ManagerMedical Science Liaison
Worked on KLOXXADO at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.